Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 9856140, 12 pages
https://doi.org/10.1155/2017/9856140
Review Article

Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms

1Clinic of Endocrine Oncology, Section of Endocrinology, Department of Pathophysiology, National and Kapodistrian University of Athens Medical School, Laiko University Hospital, Athens, Greece
2Department of Gastroenterology, Athens General Hospital “Georgios Gennimatas”, Athens, Greece

Correspondence should be addressed to Krystallenia I. Alexandraki; moc.liamg@kikardnaxela

Received 8 June 2017; Accepted 2 October 2017; Published 19 November 2017

Academic Editor: Peyman Björklund

Copyright © 2017 Krystallenia I. Alexandraki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Dasari, C. Shen, D. Halperin et al., “Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States,” JAMA Oncology, vol. 3, no. 10, pp. 1335–1342, 2017. View at Publisher · View at Google Scholar
  2. G. A. Kaltsas, G. M. Besser, and A. B. Grossman, “The diagnosis and medical management of advanced neuroendocrine tumors,” Endocrine Reviews, vol. 25, no. 3, pp. 458–511, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Kaltsas, A. Rockall, D. Papadogias, R. Reznek, and A. B. Grossman, “Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours,” European Journal of Endocrinology, vol. 151, no. 1, pp. 15–27, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Oberg, “Neuroendocrine gastrointestinal tumors—a condensed overview of diagnosis and treatment,” Annals of Oncology, vol. 10, supplement 2, pp. S3–S8, 1999. View at Publisher · View at Google Scholar
  5. I. M. Modlin, S. F. Moss, D. C. Chung, R. T. Jensen, and E. Snyderwine, “Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors,” Journal of the National Cancer Institute, vol. 100, no. 18, pp. 1282–1289, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. I. M. Modlin, K. Oberg, D. C. Chung et al., “Gastroenteropancreatic neuroendocrine tumours,” The Lancet Oncology, vol. 9, no. 1, pp. 61–72, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Mignon, “Natural history of neuroendocrine enteropancreatic tumors,” Digestion, vol. 62, supplement 1, pp. 51–58, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Pavel, D. O'Toole, F. Costa et al., “ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site,” Neuroendocrinology, vol. 103, no. 2, pp. 172–185, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Rindi, G. Klöppel, A. Couvelard et al., “TNM staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system,” Virchows Archiv, vol. 451, no. 4, pp. 757–762, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Rindi, G. Klöppel, H. Alhman et al., “TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system,” Virchows Archiv, vol. 449, no. 4, pp. 395–401, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. J. C. Yao, M. Hassan, A. Phan et al., “One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States,” Journal of Clinical Oncology, vol. 26, no. 18, pp. 3063–3072, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. I. M. Modlin, K. D. Lye, and M. Kidd, “A 5-decade analysis of 13,715 carcinoid tumors,” Cancer, vol. 97, no. 4, pp. 934–959, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Tang, L. Gong, W. Zou et al., “Multivariate analysis of metastasis-related risk factors for patients with gastroenteropancreatic neuroendocrine tumors based on clinicopathological and endoscopic features,” Oncology Reports, vol. 36, no. 6, pp. 3343–3352, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Perren, A. Couvelard, J.-Y. Scoazec et al., “ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: pathology: diagnosis and prognostic stratification,” Neuroendocrinology, vol. 105, no. 3, pp. 196–200, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Öberg, U. Knigge, D. Kwekkeboom, and A. Perren, “Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 23, supplement 7, pp. vii124–vii130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. I. M. Modlin, A. Frilling, R. R. Salem et al., “Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies,” Surgery, vol. 159, no. 1, pp. 336–347, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. M. E. Caplin, J. R. Buscombe, A. J. Hilson, A. L. Jones, A. F. Watkinson, and A. K. Burroughs, “Carcinoid tumour,” The Lancet, vol. 352, no. 9130, pp. 799–805, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. M. H. Kulke and R. J. Mayer, “Carcinoid tumors,” The New England Journal of Medicine, vol. 340, no. 11, pp. 858–868, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Fedele, Ed.“Hereditary neuroendocrine tumor syndromes,” in Hot Topics in Endocrine and Endocrine-Related Diseases, chapter 1, InTech, Rijeka, Croatia, 2013. View at Publisher · View at Google Scholar
  20. S. W. J. Lamberts, E. P. Krenning, and J.-C. Reubi, “The role of somatostatin and its analogs in the diagnosis and treatment of tumors,” Endocrine Reviews, vol. 12, no. 4, pp. 450–482, 1991. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Srirajaskanthan, J. Watkins, L. Marelli, K. Khan, and M. E. Caplin, “Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies,” Neuroendocrinology, vol. 89, no. 3, pp. 308–314, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. D. J. Kwekkeboom, E. P. Krenning, R. Lebtahi et al., “ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs,” Neuroendocrinology, vol. 90, no. 2, pp. 220–226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. D. J. Kwekkeboom, E. P. Krenning, K. Scheidhauer et al., “ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111) In-pentetreotide,” Neuroendocrinology, vol. 90, no. 2, pp. 184–189, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Boutzios and G. Kaltsas, “Clinical syndromes related to gastrointestinal neuroendocrine neoplasms,” Frontiers of Hormone Research, vol. 44, pp. 40–57, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Grozinsky-Glasberg, A. B. Grossman, and D. J. Gross, “Carcinoid heart disease: from pathophysiology to treatment—‘something in the way it moves’,” Neuroendocrinology, vol. 101, no. 4, pp. 263–273, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. L. K. Kvols, J. K. Martin, H. M. Marsh, and C. G. Moertel, “Rapid reversal of carcinoid crisis with a somatostatin analogue,” The New England Journal of Medicine, vol. 313, no. 19, pp. 1229-1230, 1985. View at Publisher · View at Google Scholar · View at Scopus
  27. I. M. Modlin, M. Pavel, and M. Kidd, “Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours,” Alimentary Pharmacology & Therapeutics, vol. 31, no. 2, pp. 169–188, 2010. View at Google Scholar
  28. D. O'Toole, M. Ducreux, G. Bommelaer et al., “Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance,” Cancer, vol. 88, no. 4, pp. 770–776, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Anthony and A. I. Vinik, “Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period,” Pancreas, vol. 40, no. 7, pp. 987–994, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Ferolla, A. Faggiano, F. Grimaldi et al., “Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses,” Journal of Endocrinological Investigation, vol. 35, no. 3, pp. 326–331, 2012. View at Google Scholar
  31. J. Strosberg, J. Weber, M. Feldman, J. Goldman, K. Almhanna, and L. Kvols, “Above-label doses of octreotide-LAR in patients with metastatic small intestinal carcinoid tumors,” Gastrointestinal Cancer Research, vol. 6, no. 3, pp. 81–85, 2013. View at Google Scholar · View at Scopus
  32. J. R. Strosberg, A. B. Benson, L. Huynh et al., “Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: A multicenter retrospective chart review study,” The Oncologist, vol. 19, no. 9, pp. 930–936, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. E. M. Wolin, B. Jarzab, B. Eriksson et al., “Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues,” Drug Design, Development and Therapy, vol. 9, pp. 5075–5086, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. E. T. Janson and K. Öberg, “Long-term management of the carcinoid syndrome treatment with octreotide alone and in combination with alpha-interferon,” Acta Oncologica, vol. 32, no. 2, pp. 225–229, 1993. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Faiss, U.-F. Pape, M. Böhmig et al., “Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group,” Journal of Clinical Oncology, vol. 21, no. 14, pp. 2689–2696, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Arnold, A. Rinke, K.-J. Klose et al., “Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: A randomized trial,” Clinical Gastroenterology and Hepatology, vol. 3, no. 8, pp. 761–771, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. M. H. Kulke, T. O'Dorisio, A. Phan et al., “Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide,” Endocrine-Related Cancer, vol. 21, no. 5, pp. 705–714, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Pavel, D. Hörsch, M. Caplin, J. Ramage, T. Seufferlein, and J. Valle, “Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial,” The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 4, pp. 1511–1519, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. H.-B. Fiebrich, G. Van Den Berg, I. P. Kema et al., “Deficiencies in fat-soluble vitamins in long-term users of somatostatin analogue,” Alimentary Pharmacology & Therapeutics, vol. 32, no. 11-12, pp. 1398–1404, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Mancuso, A. D. Kaye, J. P. Boudreaux et al., “Carcinoid syndrome and perioperative anesthetic considerations,” Journal of Clinical Anesthesia, vol. 23, no. 4, pp. 329–341, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. M. E. Condron, S. J. Pommier, and R. F. Pommier, “Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis,” Surgery, vol. 159, no. 1, pp. 358–365, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Kaltsas, M. Caplin, P. Davies et al., “ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: pre- and perioperative therapy in patients with neuroendocrine tumors,” Neuroendocrinology, vol. 105, no. 3, pp. 245–254, 2017. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Seymour and S. C. Sawh, “Mega-dose intravenous octreotide for the treatment of carcinoid crisis: A systematic review,” Canadian Journal of Anesthesia, vol. 60, no. 5, pp. 492–499, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. W. W. De Herder, E. Van Schaik, D. Kwekkeboom, and R. A. Feelders, “New therapeutic options for metastatic malignant insulinomas,” Clinical Endocrinology, vol. 75, no. 3, pp. 277–284, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. G. K. Dimitriadis, M. O. Weickert, H. S. Randeva, G. Kaltsas, and A. Grossman, “Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours,” Endocrine-Related Cancer, vol. 23, no. 9, pp. R423–R436, 2016. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Tirosh, S. M. Stemmer, E. Solomonov et al., “Pasireotide for malignant insulinoma,” Hormones, vol. 15, no. 2, pp. 271–276, 2016. View at Publisher · View at Google Scholar · View at Scopus
  47. M. H. Kulke, E. K. Bergsland, and J. C. Yao, “Glycemic control in patients with insulinoma treated with everolimus,” The New England Journal of Medicine, vol. 360, no. 2, pp. 195–197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. V. Bernard, C. Lombard-Bohas, M.-C. Taquet et al., “Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia,” European Journal of Endocrinology, vol. 168, no. 5, pp. 665–674, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. T. Ito, H. Igarashi, and R. T. Jensen, “Zollinger-Ellison syndrome: Recent advances and controversies,” Current Opinion in Gastroenterology, vol. 29, no. 6, pp. 650–661, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. R. T. Jensen, G. Cadiot, M. L. Brandi et al., “ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: Functional pancreatic endocrine tumor syndromes,” Neuroendocrinology, vol. 95, no. 2, pp. 98–119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. E. A. Lew, J. R. Pisegna, J. A. Starr et al., “Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome,” Gastroenterology, vol. 118, no. 4, pp. 696–704, 2000. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Fossmark, O. Sordal, C. S. Jianu et al., “Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A,” Alimentary Pharmacology & Therapeutics, vol. 36, no. 11-12, pp. 1067–1075, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. G. Kaltsas, I. I. Androulakis, W. W. De Herder, and A. B. Grossman, “Paraneoplastic syndromes secondary to neuroendocrine tumours,” Endocrine-Related Cancer, vol. 17, no. 3, pp. R173–R193, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. L. de Mestier, T. Walter, H. Brixi, C. Lombard-Bohas, and G. Cadiot, “Sunitinib achieved fast and sustained control of VIPoma symptoms,” European Journal of Endocrinology, vol. 172, no. 1, pp. K1–K3, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Pavel, J. W. Valle, B. Eriksson et al., “ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: systemic therapy—biotherapy and novel targeted agents,” Neuroendocrinology, vol. 105, no. 3, pp. 266–280, 2017. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Baldelli, A. Barnabei, L. Rizza et al., “Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives,” Frontiers in Endocrinology, vol. 5, article 7, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. B. Eriksson, J. Renstrup, H. Imam, and K. Öberg, “High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects,” Annals of Oncology, vol. 8, no. 10, pp. 1041–1044, 1997. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Faiss, U. Räth, U. Mansmann et al., “Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors,” Digestion, vol. 60, no. 5, pp. 469–476, 1999. View at Publisher · View at Google Scholar · View at Scopus
  59. M. di Bartolomeo, E. Bajetta, R. Buzzoni et al., “Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: a study by the Italian Trials in Medical Oncology Group,” Cancer, vol. 77, no. 2, pp. 402–408, 1996. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Arnold, R. Benning, C. Neuhaus, M. Rolwage, and M. E. Trautmann, “Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group,” Digestion, vol. 54, no. 1, pp. 72–75, 1993. View at Publisher · View at Google Scholar · View at Scopus
  61. R. Arnold, M. E. Trautmann, W. Creutzfeldt et al., “Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours,” Gut, vol. 38, no. 3, pp. 430–438, 1996. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Saltz, B. Trochanowski, M. Buckley et al., “Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors,” Cancer, vol. 72, no. 1, pp. 244–248, 1993. View at Publisher · View at Google Scholar · View at Scopus
  63. F. Panzuto, M. Di Fonzo, E. Iannicelli et al., “Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma,” Annals of Oncology, vol. 17, no. 3, pp. 461–466, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Rinke, H.-H. Müller, C. Schade-Brittinger et al., “Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group,” Journal of Clinical Oncology, vol. 27, no. 28, pp. 4656–4663, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. M. E. Caplin, M. Pavel, J. B. Ćwikła et al., “Lanreotide in metastatic enteropancreatic neuroendocrine tumors,” The New England Journal of Medicine, vol. 371, no. 3, pp. 224–233, 2014. View at Publisher · View at Google Scholar
  66. M. E. Caplin, M. Pavel, J. B. Ćwikła et al., “Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study,” Endocrine-Related Cancer, vol. 23, no. 3, pp. 191–199, 2016. View at Publisher · View at Google Scholar · View at Scopus
  67. Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg (CLARINET FORTE) https://clinicaltrials.gov/ct2/show/NCT02651987.
  68. A. Faggiano, A. C. Carratù, E. Guadagno et al., “Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: An observational retrospective-prospective analysis from real life,” Oncotarget , vol. 7, no. 5, pp. 5538–5547, 2016. View at Publisher · View at Google Scholar · View at Scopus
  69. L. K. Kvols, K. E. Oberg, T. M. O'Dorisio et al., “Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study,” Endocrine-Related Cancer, vol. 19, no. 5, pp. 657–666, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Rinke, M. Wittenberg, C. Schade-Brittinger et al., “Placebo controlled, double blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results on long term survival,” Neuroendocrinology, vol. 104, no. 1, pp. 26–32, 2017. View at Publisher · View at Google Scholar · View at Scopus
  71. A. I. Vinik, L. Anthony, J. P. Boudreaux et al., “Neuroendocrine tumors: A critical appraisal of management strategies,” Pancreas, vol. 39, no. 6, pp. 801–818, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. I. M. Modlin, M. Kidd, R. Pfragner, G. N. Eick, and M. C. Champaneria, “The functional characterization of normal and neoplastic human enterochromaffin cells,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 6, pp. 2340–2348, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. J. C. Yao, K. A. Guthrie, C. Moran et al., “Phase III prospective randomized comparison trial of depot octreotide plus interferon Alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518,” Journal of Clinical Oncology, vol. 35, no. 15, pp. 1695–1703, 2017. View at Publisher · View at Google Scholar
  74. G. Vitale, W. W. de Herder, P. M. van Koetsveld et al., “IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro,” Cancer Research, vol. 66, no. 1, pp. 554–562, 2006. View at Google Scholar
  75. R. Garcia-Carbonero, A. Rinke, J. W. Valle et al., “ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic therapy 2: chemotherapy,” Neuroendocrinology, vol. 105, no. 3, pp. 281–294, 2017. View at Publisher · View at Google Scholar · View at Scopus
  76. C. G. Moertel, M. Lefkopoulo, S. Lipsitz, R. G. Hahn, and D. Klaassen, “Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma,” The New England Journal of Medicine, vol. 326, no. 8, pp. 519–523, 1992. View at Publisher · View at Google Scholar · View at Scopus
  77. M. A. Kouvaraki, J. A. Ajani, P. Hoff et al., “Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas,” Journal of Clinical Oncology, vol. 22, no. 23, pp. 4762–4771, 2004. View at Google Scholar
  78. Y. Octavia, C. G. Tocchetti, K. L. Gabrielson, S. Janssens, H. J. Crijns, and A. L. Moens, “Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies,” Journal of Molecular and Cellular Cardiology, vol. 52, no. 6, pp. 1213–1225, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. P. Clewemar Antonodimitrakis, A. Sundin, C. Wassberg, D. Granberg, B. Skogseid, and B. Eriksson, “Streptozocin and 5-fluorouracil for the treatment of pancreatic neuroendocrine tumors: efficacy, prognostic factors and toxicity,” Neuroendocrinology, vol. 103, no. 3-4, pp. 345–353, 2016. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Koumarianou, G. Kaltsas, and M. H. Kulke, “Temozolomide in advanced neuroendocrine neoplasms: pharmacological and clinical aspects,” Neuroendocrinology, vol. 101, no. 4, pp. 274–288, 2015. View at Publisher · View at Google Scholar · View at Scopus
  81. M. H. Kulke, K. Stuart, P. C. Enzinger et al., “Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors,” Journal of Clinical Oncology, vol. 24, no. 3, pp. 401–406, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. J. R. Strosberg, R. L. Fine, J. Choi et al., “First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas,” Cancer, vol. 117, no. 2, pp. 268–275, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. R. L. Fine, A. P. Gulati, D. Tsushima et al., “Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors,” Journal of Clinical Oncology, vol. 32, supplement 3, abstract 179, 2014. View at Publisher · View at Google Scholar
  84. J. R. Strosberg, D. Coppola, D. S. Klimstra et al., “The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas,” Pancreas, vol. 39, no. 6, pp. 799-800, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Crippa, S. Partelli, G. Belfiori et al., “Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology,” World Journal of Gastroenterology, vol. 22, no. 45, pp. 9944–9953, 2016. View at Publisher · View at Google Scholar · View at Scopus
  86. E. Mitry, E. Baudin, M. Ducreux et al., “Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin,” British Journal of Cancer, vol. 81, no. 8, pp. 1351–1355, 1999. View at Publisher · View at Google Scholar · View at Scopus
  87. C. G. Moertel, L. K. Kvols, M. J. O'Connell, and J. Rubin, “Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms,” Cancer, vol. 68, no. 2, pp. 227–232, 1991. View at Publisher · View at Google Scholar · View at Scopus
  88. M. R. Druce, V. Lewington, and A. B. Grossman, “Targeted radionuclide therapy for neuroendocrine tumours: Principles and application,” Neuroendocrinology, vol. 91, no. 1, pp. 1–15, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. D. J. Kwekkeboom, W. W. de Herder, B. L. Kam et al., “Treatment with the radiolabeled somatostatin analog [177Lu- DOTA0,Tyr3] octreotate: toxicity, efficacy, and survival,” Journal of Clinical Oncology, vol. 26, no. 13, pp. 2124–2130, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. D. L. Bushnell Jr., T. M. O'Dorisio, M. S. O'Dorisio et al., “90Y-edotreotide for metastatic carcinoid refractory to octreotide,” Journal of Clinical Oncology, vol. 28, no. 10, pp. 1652–1659, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. L. Bodei, M. Kidd, G. Paganelli et al., “Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 42, no. 1, pp. 5–19, 2015. View at Publisher · View at Google Scholar · View at Scopus
  92. J. Strosberg, G. El-Haddad, E. Wolin et al., “NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for midgut neuroendocrine tumors,” The New England Journal of Medicine, vol. 376, no. 2, pp. 125–135, 2017. View at Google Scholar
  93. R. J. Hicks, D. J. Kwekkeboom, E. Krenning et al., “ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues,” Neuroendocrinology, vol. 105, no. 3, pp. 295–309, 2017. View at Publisher · View at Google Scholar
  94. A. Kasajima, M. Pavel, S. Darb-Esfahani et al., “mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours,” Endocrine-Related Cancer, vol. 18, no. 1, pp. 181–192, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. S. Faivre, M.-P. Sablin, C. Dreyer, and E. Raymond, “Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors,” Endocrinology and Metabolism Clinics of North America, vol. 39, no. 4, pp. 811–826, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. J. C. Yao, A. T. Phan, D. Z. Chang et al., “Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study,” Journal of Clinical Oncology, vol. 26, no. 26, pp. 4311–4318, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. J. C. Yao, M. H. Shah, T. Ito et al., “RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors,” The New England Journal of Medicine, vol. 364, no. 6, pp. 514–523, 2011. View at Google Scholar
  98. J. C. Yao, M. Pavel, C. Lombard-Bohas et al., “Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: Overall survival and circulating biomarkers from the randomized, Phase III RADIANT-3 study,” Journal of Clinical Oncology, vol. 34, no. 32, pp. 3906–3913, 2016. View at Publisher · View at Google Scholar · View at Scopus
  99. J. C. Yao, N. Fazio, S. Singh et al., “Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study,” The Lancet, vol. 387, no. 10022, pp. 968–977, 2016. View at Publisher · View at Google Scholar · View at Scopus
  100. M. E. Pavel, J. D. Hainsworth, E. Baudin et al., “Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study,” The Lancet, vol. 378, no. 9808, pp. 2005–2012, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. E. Raymond, “Sunitinib malate for the treatment of pancreatic neuroendocrine tumors,” The New England Journal of Medicine, vol. 364, no. 6, pp. 501–513, 2011. View at Google Scholar
  102. M. E. Pavel, E. Baudin, K. E. Öberg et al., “Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study,” Annals of Oncology, vol. 28, no. 7, pp. 1569–1575, 2017. View at Publisher · View at Google Scholar
  103. J. C. Yao, A. Phan, P. M. Hoff et al., “Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase ii study of depot octreotide with bevacizumab and pegylated interferon alfa-2b,” Journal of Clinical Oncology, vol. 26, no. 8, pp. 1316–1323, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. M. H. Kulke, J. Bendell, L. Kvols et al., “Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors,” Journal of Hematology & Oncology, vol. 4, article 29, 2011. View at Google Scholar
  105. M. H. Kulke, L. L. Siu, J. E. Tepper et al., “Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting,” Journal of Clinical Oncology, vol. 29, no. 7, pp. 934–943, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. P. T. Nghiem, S. Bhatia, E. J. Lipson et al., “PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma,” The New England Journal of Medicine, vol. 374, no. 26, pp. 2542–2552, 2016. View at Google Scholar
  107. J. M. Zaretsky, A. Garcia-Diaz, D. S. Shin et al., “Mutations associated with acquired resistance to PD-1 blockade in melanoma,” The New England Journal of Medicine, vol. 375, no. 9, pp. 819–829, 2016. View at Publisher · View at Google Scholar
  108. A. Patnaik, S. P. Kang, D. Rasco et al., “Phase I study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors,” Clinical Cancer Research, vol. 21, no. 19, pp. 4286–4293, 2015. View at Publisher · View at Google Scholar · View at Scopus